UBX
UBX Real Time Price USDRecent trades of UBX by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by UBX's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
UBX Revenue by Segment or Geography
New patents grants
-
Patent Title: Acyl sulfonamides that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Feb. 11, 2025
-
Patent Title: Antibodies directed to tie-2 and methods of use Jan. 14, 2025
-
Patent Title: Methods of treating retinal vasculopathies Apr. 09, 2024
-
Patent Title: Methods of inhibiting pathological angiogenesis Jan. 09, 2024
-
Patent Title: Methods of inhibiting pathological angiogenesis Sep. 28, 2021
-
Patent Title: Acylsulfonamide derivatives for treating senescence-associated diseases and disorders Sep. 07, 2021
-
Patent Title: Acyl sulfonamides that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Apr. 20, 2021
-
Patent Title: Conjugates that are configured for targeted delivery of therapeutic compounds to senescent cells Aug. 18, 2020
-
Patent Title: Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Aug. 18, 2020
-
Patent Title: Phosphonamidates that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Aug. 11, 2020
-
Patent Title: Acyl sulfonamides that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Jul. 21, 2020
-
Patent Title: Acyl phosphonamidates and acyl benzylamines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Jul. 07, 2020
-
Patent Title: Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer Jun. 23, 2020
-
Patent Title: Technology to inhibit vascular changes that lead to vision loss in the eye Mar. 17, 2020
-
Patent Title: Composition comprising a gene vector that selectively depletes p16 positive senescent cells Feb. 04, 2020
-
Patent Title: Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer Dec. 31, 2019
-
Patent Title: Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (pi3k) inhibitor Dec. 31, 2019
-
Patent Title: Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss Nov. 19, 2019
-
Patent Title: Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye Nov. 19, 2019
-
Patent Title: Chemical entities that kill senescent cells for use in treating age-related disease Oct. 01, 2019
-
Patent Title: Replication conditional virus that specifically kills senescent cells Aug. 13, 2019
-
Patent Title: Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use Jun. 25, 2019
-
Patent Title: Use of sulfonamide inhibitors of bcl-2 and bcl-xl to treat ophthalmic disease by selectively removing senescent cells Jun. 25, 2019
-
Patent Title: Immunogenic compositions for inducing an immune response for elimination of senescent cells May. 07, 2019
-
Patent Title: Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen Apr. 16, 2019
-
Patent Title: Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population Feb. 26, 2019
-
Patent Title: Chemical entities that kill senescent cells for use in treating age-related disease Feb. 05, 2019
-
Patent Title: Treatment of joint pain Nov. 20, 2018
-
Patent Title: Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Jul. 03, 2018
-
Patent Title: Treatment for osteoarthritis in a joint by administering a means for inhibiting mdm2 Jun. 12, 2018
-
Patent Title: Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use Jun. 05, 2018
-
Patent Title: Use of sulfonamide inhibitors of bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease May. 29, 2018
-
Patent Title: Drug conjugates for delivering compounds to senescent cells May. 15, 2018
-
Patent Title: Treatment for osteoarthritis by intra-articular administration of a cis-imidazoline Jan. 02, 2018
-
Patent Title: Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells Dec. 26, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to UBX
Recent picks made for UBX stock on CNBC
ETFs with the largest estimated holdings in UBX
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $UBX stock a Buy, Sell, or Hold?
- What is the price target for $UBX stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $UBX stock?
- Who owns the most shares of $UBX stock?
- What funds own $UBX stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view UBX Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.